Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells

Journal of Endocrinology

Volumn 193, Issue 3, 2007, Pages 421-433

  Treeck, Oliver ^a   Pfeiler, Georg ^a   Mitter, Diana ^a   Lattrich, Claus ^a   Piendl, Gerhard ^a   Ortmann, Olaf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FIBULIN; MESSENGER RNA; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; EXON; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; UPREGULATION;

ALTERNATIVE SPLICING; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR BETA; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFECTION; WOUND HEALING;

EID: 34447096900     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/JOE-07-0087     Document Type: Article

References (42)

1. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG & Lopez AM 2003 Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the women's health initiative randomized trial. JAMA 290 1739-1748.
2. Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V & Pujol P 2005 Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146 760-768.
3. Brandenberger AW Tee MK & Jaffe RB 1998 Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. Journal of Clinical Endocrinology and Metabolism 83 1025-1028.
4. Burns KH, Agno JE, Chen L, Haupt B, Ogbonna SC, Korach KS & Matzuk MM 2003 Sexually dimorphic roles of steroid hormone receptor signaling in gonadal tumorigenesis. Molecular Endocrinology 17 2039-2052.
5. Cheng J, Lee EJ, Madison LD & Lazennec G 2004 Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Letters 566 169-172.
6. Couse JF, Curtis Hewitt S & Korach KS 2000 Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. Journal of Steroid Biochemistry and Molecular Biology 74 287-296.
7. Greenlee RT, Murray T, Bolden S & Wingo PA 2000 Cancer statistics. CA: A Cancer Journal for Clinicians 50 7-33.
8. Gustafsson JA 1999 Estrogen receptor beta-a new dimension in estrogen mechanism of action. Journal of Endocrinology 163 379-383.
9. Hatch KD, Beecham JB, Blessing JA & Creasman WT 1991 Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group Study of second-line therapy in 105 patients. Cancer 68 269-271.
10. Havrilesky LJ, McMahon CP, Lobenhofer EK, Whitaker R, Marks JR & Berchuck A 2001 Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. Journal of the Society for Gynecologic Investigation 8 104-113.
11. Hayashido Y, Lucas A, Rougeot C, Godyna S, Argraves WS & Rochefort H 1998 Estradiol and fibulin-1 inhibit motility ofhuman ovarian- and breast-cancer cells induced by fibronectin. International Journal of Cancer 75 654-658.
12. Helguero LA, Faulds MH, Gustafsson JA & Haldosen LA 2005 Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24 6605-6616.
13. Herynk MH & Fuqua SA 2004 Estrogen receptor mutations in human disease. Endocrine Reviews 25 869-898.
14. Jones J, Lagasse LD & Karlan BY 1994 Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecologic Oncology 53 421-426.
15. Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A & Schairer C 2002 Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288 334-341.
16. Lau KM, Mok SC & Ho SM 1999 Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. PNAS 96 5722-5727.
17. Lazennec G, Bresson D, Lucas A, Chauveau C & Vignon F 2001 ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142 4120-4130.
18. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA & OhIsson C 2003 Estrogen receptor (Ek)-beta reduces ERalpha-regulated gene transcription,supporting a 'ying yang' relationship between ERalpha and ERbeta in mice. Molecular Endocrinology 17 203-208.
19. T method. Methods 25 402-408.
20. Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC & Watson PH 1998 Estrogen receptor-beta mRNA variants in human and murine tissues. Molecular and Cellular Endocrinology 138 199-203.
21. Mak P, Leung YK, Tang WY, Harwood C & Ho SM 2006 Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 8 896-904.
22. Merchenthaler I & Shugrue PJ 1999 Estrogen receptor-beta: a novel mediator of estrogen action in brain and reproductive tissues. Morphological considerations. Journal of Endocrinological Investigation 22 10-12.
23. Moll F, Katsaros D, Lazennec G, Hellio N, Roger P, Giacalone PL, Chalbos D, Maudelonde T, Rochefort H & Pnjol P 2002 Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells. Oncogene 21 1097-1107.
24. Osborne CK & Schiff R 2005 Estrogen-receptor biology: continuing progress and therapeutic implications. Journal of Clinical Oncology 23 1616-1622.
25. Pettersson K & Gustafsson JA 2001 Role ofestrogen receptor beta in estrogen action. Annual Review of Physiology 63 165-192.
26. Planas-Silva MD & Weinberg RA 1997 Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology 17 4059-4069.
27. Poola I, Abraham J & Liu A 2002a Estrogen receptor beta splice variant mRNAs are differentially altered during breast carcinogenesis. Journal of Steroid Biochemistry and Molecular Biology 82 169-179.
28. Poola I, Abraham J & Baldwin K 2002b Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of estrogen receptor beta mRNA is distinct from that of estrogen receptor alpha. FEBS Letters 516 133-138.
29. Price RH Jr, Lorenzon N & Handa RJ 2000 Differential expression of estrogen receptor beta splice variants in rat brain: identification and characterization of a novel variant missing exon 4. Brain Research. Molecular Brain Research 80 260-268.
30. Price RH Jr, Butler CA, Webb P, Uht R, Kushner P & Handa RJ 2001 A splice variant of estrogen receptor beta missing exon 3 displays altered subnuclear localization and capacity for transcriptional activation. Endocrinology 142 2039-2049.
31. Pujol P, Rey JM, Nirde P, Roger P, Gastaldi M, Laffargue F, Rachefort H & Maudelonde T 1998 Differential expression ofestrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Research 58 5367-5373.
32. Rodriguez C, Patel AV, Calle EE, Jacob EJ & Thun MJ 2001 Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285 1460-1465.
33. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Munoz A & Mor G 2000 Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstetrics and Gynecology 96 417-421.
34. Scambia G, Benedetti-Panici P, Ferrandina G, Distefano M, Salerno G, Romanini ME, Fagotti A & Mancuso S 1995 Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. British Journal of Cancer 72 361-366.
35. Sierens JE, Scobie GA, Wilson J & Saunders PT 2004 Cloning of oestrogen receptor beta from old and new world primates: identification of splice variants and functional analysis. Journal of Molecular Endocrinology 32 703-718.
36. Speirs V, Adams IP, Walton DS & Atkin SL 2000 Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland. Journal of Clinical Endocrinology and Metabolism 85 1601-1605.
37. Ståhlberg A, Åman P, Ridell B, Mostad P & Kubista M 2003 A quantitative real-time PCR method for detection of B-Lymphocyte monoclonality by comparison of kappa and lambda immunoglobulin light chain expression. Clinical Chemistry 49 51-59.
38. Thomas TJ, Faaland CA, Adhikarakunnathu S, Watkins LF & Thomas T 1998 Induction of p21 (CIP1/WAF1/SID1) by estradiol in a breast epithelial cell line transfected with the recombinant estrogen receptor gene: a possible mechanism for a negative regulatory role of estradiol. Breast Cancer Research and Treatment 47 181-193.
39. Treeck O, Pfeiler G, Federhofer B, Houlihan H, Vollmer A, Horn F & Ortmann O 2007 Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Molecular and Cellular Endocrinology 264 50-60.
40. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons M, Birnbaum D, Nguyen C, Theillet C & Cohen PA 2004 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. Journal of Molecular Endocrinology 32 397-414.
41. Vladusic EA, Hombsby AE, Guerra-Vladusic FK & Lupa R 1998 Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Research 58 210-214.
42. Zhao C, Toresson G, Xu L, Koehler KF, Gustafsson JA & Dahlman-Wright K 2005 Mouse estrogen receptor beta isoforms exhibit differences in ligand selectivity and coactivator recruitment. Biochemistry 44 7936-7944.